|
|
Study on the regulatory network and potential mechanism of Bezoar in the treatment of cerebral infarction |
LIANG Yu-hua1 HE Hua-hua2 DENG Tai-ping3 |
1. Department of Pharmacy, Huizhou Municipal Central People′s Hospital, Guangdong Province, Huizhou 516001,China;
2. Department of Neurology, Huizhou Traditional Chinese Medicine Hospital, Guangdong Province, Huizhou 516001, China;
3. Department of Internal Medicine, Traditional Chinese Medicine Hospital of Boluo County in Huizhou City, Guangdong Province, Boluo 516100, China |
|
|
Abstract Objective To predicit the potential target of Bezoar in the treatment of cerebral infarction via network pharmacology and to explore its regulatory network and mechanism of action. Methods The main active components of Bezoar were were obtained through traditional Chinese medicine systems pharmacology database and analysis platform(TCMSP) database and literature mining, and the target of the active ingredients of Bezoar was predicted and screened using the human gene database GeneCards. String database and Cytoscape 3.7.1 software were used to draw protein interaction (PPI) network, and gene ontology (GO) analysis of potential genes was performed with the application of DAVID6.8 database. Results A total of 5 active ingredients of Bezoar were obtained by screening, involving 3 targets.GO analysis results showed that the biological process of Bezoar in the treatment of cerebral infarction mainly involved steroid hormone receptor activity, nuclear receptor activity, transcription factor activity, steroid binding, vitamin D receptor binding, nuclear receptor binding, chromatin DNA binding, and ATPase binding, etc. Conclusion The treatment of cerebral infarction by Bezoar is a complex process with multiple components and multiple targets, mainly by regulating the three targets of NR3C2, PGR and RXRA, involving nuclear receptor activity, transcription factor activity,steroid binding, vitamin D receptor binding, chromatin DNA binding, ATPase binding and other biological processes to play a role in intervening cerebral infarction.
|
|
|
|
|
[1] |
常虹.脑梗死的治疗现状及进展分析[J].继续医学教育,2019,33(1):55-57.
|
[2] |
Gold AB,Herrmann N,Lanctot KL.Lithium and its Neuroprotective and Neurotrophic Effects:Potential Treatment for Post-Ischemic Stroke Sequelae[J].Curr Drug Targets,2011,12(2):243-255.
|
[3] |
王维治.神经病学[M].2 版.北京:人民卫生出版社,2013:918.
|
[4] |
刘晓明,高善语.安宫牛黄制剂治疗老年急性脑梗死的临床观察[J].光明中医,2016,31(17):2462-2465.
|
[5] |
刘晓燕,彭凯润,杨红军,等.体外培育牛黄治疗急性脑梗死临床疗效观察[J].中国中医药信息杂志,2010,17(5):66-67.
|
[6] |
许再玲.安宫牛黄丸和肝安治疗重型极重型流行性乙型脑炎80 例[J].浙江中医杂志,1995,(7):302-303.
|
[7] |
柯荣勋.牛黄及其伪品的鉴别[J].江西中医药,2007,38(11):57-58.
|
[8] |
汝锦龙.中药系统药理学数据库和分析平台的构建和应用[D].咸阳:西北农林科技大学,2015.
|
[9] |
李明玥,倪健,尹兴斌.改善中药口服生物利用度的制剂技术研究进展[J].中华中医药学刊,2016,34(2):307-311.
|
[10] |
刘惠.基于系统药理学的甘草作用机制和新药发现研究[D].咸阳:西北农林科技大学,2013.
|
[11] |
Li J,Zhao P,Li Y,et al.Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronicobstructive pulmonary disease[J].Sci Rep,2015,5:15 290.
|
[12] |
Von Mering C,Jensen LJ,Snel B,et al.STRING:known and predicted protein-protein associations,integrated and transferred across organisms[J].Nucleic Acids Res,2005,33(Database issue):D433-D437.
|
[13] |
Martucci D,Masseroli M,Pinciroli F.Gene ontology application to genomic functional annotation,statistical analysis and knowledge mining[J].Stud Health Technol Inform,2004,102:108-131.
|
[14] |
Huang DW,Sherman BT,Lempicki RA.Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources[J].Nat Protoc,2009,4(1):44-57.
|
[15] |
Pierre SV,Yang C,Yuan Z,et al.Ouabain triggers preconditioning through activation of the Na+,K+-ATPase signaling cascade in rat hearts[J].Cardiovasc Res,2007,73(3):488-496.
|
[16] |
蔺心敬,张丽香,罗永坚,等.Na+-K+-ATP 酶活性与缺血半暗带脑组织缺血再灌注损伤的研究[J].中华老年心脑血管病杂志,2013,15(3):302-304.
|
[17] |
Kojima G,Bell C,Abbott RD,et al.Low Dietary Vitamin D Predicts 34-Year Incident Stroke The Honolulu Heart Program[J].Stroke,2012,43(8):2163-2167.
|
[18] |
Sun Q,Pan A,Hu FB,et al.25-hydroxyvitamin D levels and risk of stroke:A prospective study and meta-analysis[J].Stroke,2012,43(6):1470-1477.
|
[19] |
Cui X,Gooch H,Petty A,et al.Vitamin D and the brain:Genomicand non-genomic actions[J].Mol Cell Endocrinol,2017,453(5):131-143.
|
[20] |
Jorde R,Sneve M,Torjesen P,et al.Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline,but notaffected during supplementation with vitamin D[J].Thromb Res,2010,125(5):e210-e213.
|
|
|
|